CES 2022: Abbott CEO Robert Ford Announces New Biowearables Line For Consumers, Paving The Way From Measuring Glucose To Ketone, Lactate, Alcohol
Abbott announced today at CES 2022 it is developing a new line of consumer wearables, starting with a device to track ketones continuously, which is expected to launch in Europe this year.
You may also be interested in...
The company announced that it is developing a new biowearable device that will continuously monitor both glucose and ketone levels with one sensor.
The consumer device company recently bought 8Fit, a German fitness app developer, and Impeto Medical, the developer of the Sudoscan technology for detecting and tracking small fiber neuropathy.
In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights the push behind digital therapeutics, Abbott’s biowearable line, Exec Chats with iRhythm and Cognetivity, Right To Repair rules for tech, and FDA's guidance on 3D-printing.